Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1987 Jul;46(7):549–554. doi: 10.1136/ard.46.7.549

Nonathymulin in rheumatoid arthritis: two double blind, placebo controlled trials.

B Amor 1, M Dougados 1, C Mery 1, M Dardenne 1, J F Bach 1
PMCID: PMC1002191  PMID: 3310925

Abstract

Two randomised double blind, placebo controlled trials have been carried out to assess the effectiveness of nonathymulin, a synthetic thymic peptide hormone, in the treatment of rheumatoid arthritis (RA) and to compare three different dosage schedules (1, 5, and 10 mg/day). Nonathymulin 5 mg proved to be the most efficient dose, providing significant clinical improvement as evaluated by the global assessment of all patients who entered the trials (56% v 17% in the placebo group) (p less than 0.02) and by four objective parameters. This effect was accompanied with minimal adverse effects and was not associated with clear changes in immunological parameters. A significant correlation was observed, however, in clinical response to nonathymulin, and T cell subset imbalance was assessed using monoclonal anti-T cell antibodies and a functional suppressor T cell assay.

Full text

PDF
549

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amor B., Dougados M., Mery C., de Gery A., Choay J., Dardenne M., Bach J. F. Thymuline (FTS) in rheumatoid arthritis. Arthritis Rheum. 1984 Jan;27(1):117–118. doi: 10.1002/art.1780270124. [DOI] [PubMed] [Google Scholar]
  2. Amor B., Mery C., de Gery A. Tiopronin (N-[2-mercaptopropionyl] glycin) in rheumatoid arthritis. Arthritis Rheum. 1982 Jun;25(6):698–703. doi: 10.1002/art.1780250614. [DOI] [PubMed] [Google Scholar]
  3. Chatenoud L., Bach M. A. Abnormalities of T-cell subsets in glomerulonephritis and systemic lupus erythematosus. Kidney Int. 1981 Aug;20(2):267–274. doi: 10.1038/ki.1981.130. [DOI] [PubMed] [Google Scholar]
  4. DIAGNOSTIC criteria for rheumatoid arthritis: 1958 revision by a committee of the American Rheumatism Association. Ann Rheum Dis. 1959 Mar;18(1):49–53. [PMC free article] [PubMed] [Google Scholar]
  5. Dardenne M., Pléau J. M., Nabarra B., Lefrancier P., Derrien M., Choay J., Bach J. F. Contribution of zinc and other metals to the biological activity of the serum thymic factor. Proc Natl Acad Sci U S A. 1982 Sep;79(17):5370–5373. doi: 10.1073/pnas.79.17.5370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Feldmann J. L., Mery C., Amor B., Kahan A., de Gery A., Delbarre F. Effectiveness of levamisole in rheumatoid arthritis: Immune changes and long-term results. Scand J Rheumatol. 1981;10(1):1–8. [PubMed] [Google Scholar]
  7. Israel-Biet D., Noel L. H., Bach M. A., Dardenne M., Bach J. F. Marked reduction of DNA antibody production and glomerulopathy in thymulin (FTS-Zn) or cyclosporin A treated (NZB X NZW) F1 mice. Clin Exp Immunol. 1983 Nov;54(2):359–365. [PMC free article] [PubMed] [Google Scholar]
  8. Kahan A., Kahan A., Amor B., Menkes C. J. Different defects of T cell regulation of Epstein-Barr virus-induced B cell activation in rheumatoid arthritis. Arthritis Rheum. 1985 Sep;28(9):961–970. doi: 10.1002/art.1780280902. [DOI] [PubMed] [Google Scholar]
  9. Lee P., Jasani M. K., Dick W. C., Buchanan W. W. Evaluation of a functional index in rheumatoid arthritis. Scand J Rheumatol. 1973;2(2):71–77. doi: 10.3109/03009747309098820. [DOI] [PubMed] [Google Scholar]
  10. Malaise M. G., Hauwaert C., Franchimont P., Danneskiold-Samsoe B., Bach-Andersen R., Gross D., Gerber H., Gerschpacher H., Stocker H., Bolla K. Treatment of active rheumatoid arthritis with slow intravenous injections of thymopentin. A double-blind placebo-controlled randomised study. Lancet. 1985 Apr 13;1(8433):832–836. doi: 10.1016/s0140-6736(85)92205-6. [DOI] [PubMed] [Google Scholar]
  11. Mery C., Delrieu F., Ghozlan R., Saporta L., Simon F., Amor B., Menkes C. J., Delbarre F. Controlled trial of D-penicillamine in rheumatoid arthritis. Dose effect and the role of zinc. Scand J Rheumatol. 1976;5(4):241–247. doi: 10.3109/03009747609099913. [DOI] [PubMed] [Google Scholar]
  12. Reinherz E. L., Schlossman S. F. The differentiation and function of human T lymphocytes. Cell. 1980 Apr;19(4):821–827. doi: 10.1016/0092-8674(80)90072-0. [DOI] [PubMed] [Google Scholar]
  13. Simon R. Confidence intervals for reporting results of clinical trials. Ann Intern Med. 1986 Sep;105(3):429–435. doi: 10.7326/0003-4819-105-3-429. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES